Nevan Krogan, University of California, San Francisco
Researchers at the University of California, San Francisco, identified nine existing drugs that show promise to treat COVID-19. The proteins they target haven’t been tried before.
In Ontario, the task of deciding which treatments to use for COVID-19 patients falls to two committees that weigh the evidence and choose which drugs to use, and how to manage critical illness.
What does high blood sugar have to do with vulnerability to COVID-19? And is there a role for the controversial drug hydroxychloroquine in lowering blood sugar in COVID-19 patients?
With recent calls for their use in combating COVID-19, there are concerns that chloroquine and hydroxychloroquine might become unavailable to people who need them.
Researchers, scientific journals and health agencies are doing everything they can to speed up coronavirus research. The combination of pace and panic during this pandemic is causing mistakes.
The president promoted the combination of hydroxychloroquine and an antibiotic for treating COVID-19. But a new study suggests it provides no benefits.
A medicinal chemist addresses questions about chloroquine and hydroxychloroquine: what it is, whether it is effective against COVID-19 and whether it can treat and/or prevent this disease.
People who have rheumatoid arthritis often suffer from depression as well. For poor people this is often worse because they cut off their social networks.
Professor of Chemistry and Biochemistry and President-Elect of the International Society for Antiviral Research, University of Maryland, Baltimore County